Altered urinary excretion of aquaporin 2 in IgA nephropathy

European Journal of Endocrinology

Volumn 165, Issue 4, 2011, Pages 657-664

  Rocchetti, Maria Teresa ^a   Tamma, Grazia ^b   Lasorsa, Domenica ^b   Suriano, Ida Valentina ^a   D'Apollo, Annamaria ^a   Papale, Massimo ^a   Mastrofrancesco, Lisa ^b   Grandaliano, Giuseppe ^a   Svelto, Maria ^b   Valenti, Giovanna ^b   Gesualdo, Loreto ^b   Di Paolo, Salvatore ^c  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c Hospital Dimiccoli   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSINOGEN; AQUAPORIN 2; ARGIPRESSIN; BRADYKININ; COPEPTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HORMONE PRECURSOR; METHYLPREDNISOLONE; PREDNISONE; RAMIPRIL; STEROID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DRUG DOSE TITRATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FUNCTION; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT DURATION;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; ANTI-INFLAMMATORY AGENTS; AQUAPORIN 2; ARGININE VASOPRESSIN; BIOLOGICAL MARKERS; BRADYKININ; FEMALE; GLOMERULONEPHRITIS, IGA; GLYCOPEPTIDES; HUMANS; HYPERTENSION, RENAL; LOGISTIC MODELS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; STEROIDS;

EID: 80053498715     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0512     Document Type: Article

References (32)

1. Del Prete D, Gambaro G, Lupo A, Anglani F, Brezzi B, Magistroni R, Graziotto R, Furci L, Modena F, Bernich P, Albertazzi A, D'Angelo A & Maschio G. Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney International 2003 64 149-159. (doi:10.1046/j.1523-1755.2003.00065.x)
2. Miyake-Ogawa C, Miyazaki M, Abe K, Harada T, Ozono Y, Sakai H, Koji T & Kohno S. Tissue-specific expression of renin-angiotensin system components in IgA nephropathy. American Journal of Nephrology 2005 25 1-12. (doi:10.1159/000083224)
3. Dillon JJ. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Seminars in Nephrology 2004 24 218-224. (doi:10.1016/j.semnephrol.2004.01.003)
4. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M & Linné T. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. Journal of the American Society of Nephrology 2007 18 1880-1888. (doi:10.1681/ASN.2006040347)
5. Bolignano D & Zoccali C. Vasopressin beyond water: implications for renal diseases. Current Opinion in Nephrology and Hypertension 2010 19 499-504. (doi:10.1097/MNH.0b013e32833d35cf)
6. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovascular Research 2001 51 372-390. (doi:10.1016/S0008-6363(01)00328-5)
7. Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, Lonergan M, Ruel N, Bouby N & Bankir L. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrology, Dialysis, Transplantation 2003 18 497-506. (doi:10.1093/ndt/18.3.497)
8. Li C, Wang W, Rivard CJ, Lanaspa MA, Summer S & Schrier RW. Molecular mechanisms of angiotensin II stimulation on aquaporin-2 expression and trafficking. American Journal of Physiology. Renal Physiology 2011 300 F1255-F1261. (doi:10.1152/ajprenal.00469.2010)
9. Wen H, Frokiaer J, Kwon TH & Nielsen S. Urinary excretion of aquaporin-2 in rat is mediated by a vasopressin-dependent apical pathway. Journal of the American Society of Nephrology 1999 10 1416-1429. (Pubitemid 29297516)
10. Lee KSM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH & Katz AI. IgA nephropathy: morphologic predictors of progressive renal disease. Human Pathology 1982 13 314-322. (doi:10.1016/S0046-8177(82)80221-9)
11. Valenti G, Laera A, Gouraud S, Pace G, Aceto G, Penza R, Selvaggi FP & Svelto M. Low-calcium diet in hypercalciuric enuretic children restores AQP2 excretion and improves clinical symptoms. American Journal of Physiology. Renal Physiology 2002 283 F895-F903. (doi:10.1152/ajprenal.00354.2001)
12. Morgenthaler NG, Struck J, Alonso C & Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clinical Chemistry 2006 52 112-119. (doi:10.1373/clinchem.2005. 060038)
13. Jaspard E, Wei L & Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. Journal of Biological Chemistry 1993 268 9496-9503. (Pubitemid 23146003)
14. Tamma G, Carmosino M, Svelto M & Valenti G. Bradykinin signaling counteracts cAMP-elicited aquaporin 2 translocation in renal cells. Journal of the American Society of Nephrology 2005 16 2881-2889. (doi:10.1681/ASN. 2005020190)
15. Coppo R, Amore A, Gianoglio B, Cacace G, Picciotto G, Roccatello D, Peruzzi L, Piccoli G & De Filippi PG. Angiotensin II local hyperreactivity in the progression of IgA nephropathy. American Journal of Kidney Diseases 1993 21 593-602. (Pubitemid 23178474)
16. Nishiyama A, Konishi Y, Ohashi N, Morikawa T, Urushihara M, Maeda I, Hamada M, Kishida M, Hitomi H, Shirahashi N, Kobori H & Imanishi M. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrology, Dialysis, Transplantation 2011 26 170-177. (doi:10.1093/ndt/gfq371)
17. Kim SM, Jang HR, Lee YJ, Lee JE, Huh WS, Kim DJ, Oh HY &Kim YG. Urinary angiotensinogen levels reflect the severity of renal histopathology in patients with chronic kidney disease. Clinical Nephrology 2011 76 117-123. (doi:10.5414/CN107045)
18. Yamamoto T, Nakagawa T, Suzuki H, Ohashi N, Fujigaki Y, Kato A, Nakamura Y, Suzuki F & Hishida A. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. Journal of the American Society of Nephrology 2007 18 1558-1565. (doi:10.1681/ASN.2006060554)
19. Kobori H, Urushihara M, Xu JH, Berenson GS & Navar LG. Urinary angiotensinogen is correlated with blood pressure in men (Bogalusa Heart Study). Journal of Hypertension 2010 28 1422-1428. (doi:10.1097/HJH.0b013e3283392673)
20. Buemi M, Nostro L, Di Pasquale G, Cavallaro E, Sturiale A, Floccari F, Aloisi C, Ruello A, Calapai G, Corica F & Frisina N. Aquaporin-2 water channels in spontaneously hypertensive rats. American Journal of Hypertension 2004 17 1170-1178. (doi:10.1016/j.amjhyper.2004.07.003)
21. Watts AG. Glucocorticoid regulation of peptide genes in neuroendocrine CRH neurons: a complexity beyond negative feedback. Frontiers in Neuroendocrinology 2005 26 109-130. (doi:10.1016/j.yfrne.2005.09.001)
22. Bähr V, Franzen N, Oelkers W, Pfeiffer AF & Diederich S. Effect of exogenous glucocorticoid on osmotically stimulated antidiuretic hormone secretion and on water reabsorption in man. European Journal of Endocrinology 2006 155 845-848. (doi:10.1530/eje.1.02299)
23. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE & Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987 237 268-275. (doi:10.1126/science.3037703)
24. De Seigneux S, Nielsen J, Olesen ET, Dimke H, Kwon TH, Frøkiaer J & Nielsen S. Long-term aldosterone treatment induces decreased apical but increased basolateral expression of AQP2 in CCD of rat kidney. American Journal of Physiology. Renal Physiology 2007 293 F87-F99. (doi:10.1152/ajprenal.00431. 2006)
25. De Haij S, Adcock IM, Bakker AC, Gobin SJ, Daha MR & van Kooten C. Steroid responsiveness of renal epithelial cells. Dissociation of transrepression and transactivation. Journal of Biological Chemistry 2003 278 5091-5098. (doi:10.1074/jbc.M209836200)
26. Chansel D, Llorens-Cortes C, Vandermeersch S, Pham P & Ardaillou R. Regulation of angiotensin II receptor subtypes by dexamethasone in rat mesangial cells. Hypertension 1996 27 867-874. (Pubitemid 26113833)
27. Kobori H, Prieto-Carrasquero MC, Ozawa Y & Navar LG. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension 2004 43 1126-1132. (doi:10.1161/01.HYP.0000122875. 91100.28)
28. Manno C, Torres DD, Rossini M, Pesce F & Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrology, Dialysis, Transplantation 2009 24 3694-3701. (doi:10.1093/ndt/gfp356)
29. Meijer E, Bakker SJ, Halbesma N, De Jong PE, Struck J &Gansevoort RT. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney International 2010 77 29-36. (doi:10.1038/ki.2009.397)
30. Perico N, Zoja C, Corna D, Rottoli D, Gaspari F, Haskell L &Remuzzi G. V1/V2 vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney International 2009 76 960-967. (doi:10.1038/ki.2009.267)
31. Santucci A, Leonetti Luparini R, Ferri C, Ficara C, Giarrizzo C &Balsano F. Relationship between vasopressin and the renin-angiotensin- aldosterone system in essential hypertension: effect of converting enzyme inhibitor on plasma vasopressin. Journal of Hypertension 1985 3 (Suppl.) S133-S134. (Pubitemid 16129477)
32. Armando I, Carranza A, Nishimura Y, Hoe KL, Barontini M, Terrón JA, Falcón-Neri A, Ito T, Juorio AV & Saavedra JM. Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation stress. Endocrinology 2001 142 3880-3889. (doi:10.1210/en.142.9.3880)